Idazoxan treatment in progressive supranuclear palsy

Neurology

Volumn 41, Issue 7, 1991, Pages 986-991

  Ghika, J ^a   Tennis, M ^a   Hoffman, E ^a   Schoenfeld, D ^a   Growdon, J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDAZOXAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DEMENTIA; DEPRESSION; DIOXANES; FEMALE; GAIT; HUMAN; IDAZOXAN; MALE; MOVEMENT; SEVERITY OF ILLNESS INDEX; SUPPORT, U.S. GOV'T, P.H.S.; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0026080021     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.41.7.986     Document Type: Article

References (53)

1. Steele JC, Richardson JC, Olszewsky J. Progressive supranuclear palsy. Arch Neurol 1964;10:121-130.
2. Jellinger K, Riederer P, Tomonga M. Progressive supranuclear palsy: clinical-pathological and biochemical studies. J Neural Transm 1980;16:111-128.
3. Kish SH, Chang LK, Mirchandani L, et al. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 1985;18:530-536.
4. Agid Y, Javoy-Agid J, Ruberg M, et al. Progressive supranuclear palsy: anatomo-clinical and biochemical considerations. In: Yahr MD, Bergman KJ, eds. Advances in neurology, vol 45. New York: Raven Press, 1986:191-206.
5. Agid Y, Graybiel AM, Ruberg M, et id. The efficacy of levodopa treatment declines in the course of Parkinson’s disease: do non-dopaminergic lesions play a role? In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Parkinson’s disease: anatomy, pathology, and therapy. Advances in neurology, vol. 53. New York: Raven Press, 1990:83-100.
6. VanDongen PAM. The human locus coeruleus in neurology and psychiatry. Prog Neurobiol 1981;17:91-139.
7. Mann DMA, Yates PO, Hawkes J. The physiology of human locus coeruleus. Clin Neuropathol 1983;2:1-17.
8. Loughlin SE, Foote SL, Bloom FE. Efferent projections of nucleus locus coeruleus: topographic organization of cells of origin demonstrated by three-dimensional reconstruction. Neuroscience 1986;18:291-306.
9. Jerussi TP, Caparchione JF, Benvenga MJ. Reversal of opioid muscular rigidity in rats: evidence for alpha-2 adrenergic involvement. Pharmacol Biochem Behav 1987;28:283-289.
10. Lui PW, Lee TY, Chan SHH. Involvement of the locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Neurosci Lett 1989;96:114-119.
11. Mason ST. Noradrenaline in the brain: progress in theories of behavioral function. Prog Neurobiol 1981;16:263-303.
12. Scriabine A, Clinenschmidt BV, Sweet CS. Central noradrenergic control of blood pressure. Annu Rev Pharmacol Toxicol 1976;16:113-123.
13. Kuru M. Nervous control of micturition. Physiol Rev 1965;45:425-494.
14. Mason ST. Catecholamines and behavior. Cambridge, UK: Cambridge University Press, 1984.
15. Amaral DG. Locus coeruleus and learning. Science 1975;188:377-378.
16. Amsten AFT, Goldman-Rakic PS. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230:1273-1276.
17. Chapleo CB, Roach AG, Walter DS, et al. RX 781094, a new potent selective antagonist of alpha-2 adrenoceptors [Abstract]. Br J Pharmacol 1981;74:842.
18. Freedman JE, Aghajanian GK. Idazoxan (RX 781094) selectively antagonizes alpha-2 adrenoreceptors on rat central neurons. Eur J Pharmacol 1984;105:205-265.
19. Doxey JC, Lane AC, Roach ET, et al. Comparison of the alpha-adrenoreceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and coryanthine. Naunyn Schmiedebergs Arch Pharmacol 1984;325:136-144.
20. Wikberg JES, Staffan U. Further characterization of the guinea pig cerebral cortex idazoxan receptor: solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug. J Neurochem 1990;55:192-203.
21. Ghika J, Tennis M, Growdon JH. Idazoxan improves motor performance in progressive supranuclear palsy (PSP) [Abstract]. Neurology 1990;40(suppl 1):438.
22. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38:1031-1034.
23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
24. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
25. Blessed G, Tomlinson BE, Roth M. Diagnostic and statistical manual of mental disorders, 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987.
26. Foster NL, Gilman S, Berent S, et al. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988;24:399-406.
27. Johnson KA, Sperling RA, Holman BL, et al. 123I-IMP-SPECT in progressive supranuclear palsy [Abstract]. Neurology 1989;(suppl 1):204.
28. Blin J, Baron CJC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinical-metabolic correlations. Arch Neurol 1990;47:747-752.
29. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC, eds. Third symposiun on Parkinson’s disease. Edinburgh, Scotland: E and L Livingstone, 1969:152-157.
30. Lang AE, Fahn S. Assessment of Parkinson’s disease. In: Munsat TL, ed. Quantification of neurologic deficit. Woburn, MA: Butterworths, 1989:271-284.
31. Bass BM, Stucki RE. A note on a modified Purdue pegboard. J Applied Psychol 1951;35:312-313.
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1967;5:135-140.
33. Yesavage JA, Brink TL. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiat Res 1983;17:37-49.
34. Randt CT, Brown ER, Osborne DP. A memory test for longitudinal measurement of mild to moderate deficits. Clin Neuropsychol 1980;2:184-194.
35. Flowers KA, Robertson C. The effect of Parkinson’s disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry 1985;48:517-529.
36. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
37. Golden CJ, Hammeke TA, Purisch AD. Manual for the Luria-Nebraska neuropsychological battery. Los Angeles: Western Psychological Services, 1980.
38. Wechsler D. Wechsler adult intelligence scale, revised. New York: Psychological Corporation, 1981.
39. Armitage P, Hills H. The two-period crossover trial. The Statistician 1982;31:119.
40. Klawans HL, Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol 1971;5:115-129.
41. Jankovic J. Treatment of Parkinson’s disease and progressive supranuclear palsy: a controlled trial of pergolide mesylate. [Abstract], Neurology 1982;32:A182.
42. Neophytides A, Liberman AN, Goldstein M, et al. The use of lisuride, a potent dopamine and serotonin agonist in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1982;45:261-263.
43. Foster NL, Aldrich MS, Bluemlin L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989;39:257-261.
44. Paulson GW, Lowery HW, Taylor GC. Progressive supranuclear palsy: pneumoencephalography, electronystagmography, and treatment with methysergide. Eur Neurol 1981;20:13-16.
45. Rafal RD, Grimm RJ. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology 1981;31:1507-1518.
46. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985;35:1189-1193.
47. Growdon JH. Tyrosine treatment in Parkinson’s disease: clinical effects [Abstract]. Neurology 1981;31:134.
48. Narabayashi H, Timohoshi K, Yokochi F, Nagatsu T. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia. In: Yahr MD, Bergmann KJ, eds. Parkinson’s disease. Advances in neurology, vol. 45. New York: Raven Press, 1986:550-559.
49. Pamavelas JG, Papadopoulos GC. The monoaminergic innervation of the cerebral cortex is not diffuse nor specific. Trends Neurosci 1989;12:315-319.
50. Westlund KW, Bowker RM, Ziegler MG, et al. Origin and termination of descending noradrenergic projections to the spinal cord of the monkey. Brain Res 1984;292:1-16.
51. Langer SZ. Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974;23:1793-1800.
52. Lopez G-Coviella I, Logue M, Growdon JH, Wurtman RJ. Central effects of L-threo-DOPS and other noradrenergic drugs on norepinephrine turnover in rats [Abstract]. Neurology 1986;36(suppl 1):98.
53. Chamey DS, Heninger GR, Redmond DE. Yohimbine-induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sei 1983;33:19-29.